Published in Eur J Neurol on December 07, 2012
Can we predict the evolution of an unpredictable disease like multiple sclerosis? Eur J Neurol (2012) 0.80
Personalization and Patient Involvement in Decision Support Systems: Current Trends. Yearb Med Inform (2015) 0.79
How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication? A Qualitative Study. PLoS One (2016) 0.78
Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One (2017) 0.75
Assessment and comparison of prognostic classification schemes for survival data. Stat Med (1999) 5.94
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
Psychological responses of patients receiving a diagnosis of cancer. Ann Oncol (2003) 1.58
Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol (2009) 1.27
Prognosticating futures and the human experience of hope. Palliat Support Care (2007) 1.14
How to assess prognostic models for survival data: a case study in oncology. Methods Inf Med (2003) 1.12
Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak (2007) 1.04
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry (2007) 1.02
'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. Soc Sci Med (2004) 0.99
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 16.46
A viral movement protein prevents spread of the gene silencing signal in Nicotiana benthamiana. Cell (2000) 4.70
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Processing of complex sounds in the macaque nonprimary auditory cortex. Science (1995) 3.98
An SV40 "enhancer trap" incorporates exogenous enhancers or generates enhancers from its own sequences. Cell (1984) 3.61
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol (1998) 3.55
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science (1998) 3.04
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.74
Bunyamwera bunyavirus nonstructural protein NSs is a nonessential gene product that contributes to viral pathogenesis. Proc Natl Acad Sci U S A (2001) 2.63
MRI as an outcome in multiple sclerosis clinical trials. Neurology (2008) 2.62
Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology (2005) 2.53
CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology (2001) 2.16
High frequency of homologous recombination in mammalian cells between endogenous and introduced SV40 genomes. Cell (1985) 2.14
[Guideline-conforming interventional treatment of acute ST-segment elevation myocardial infarction in rural areas using network collaboration]. Dtsch Med Wochenschr (2004) 2.11
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07
Disability as an outcome in MS clinical trials. Neurology (2008) 2.01
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Possible transfer of Pneumocystis carinii between immunodeficient patients. Lancet (1990) 1.88
Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev (2001) 1.88
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86
Salicylic acid-inducible binding of a tobacco nuclear protein to a 10 bp sequence which is highly conserved amongst stress-inducible genes. Plant J (1993) 1.84
Crossing over in the chromosomal region determining amylase isozymes in Drosophila melanogaster. Hereditas (1967) 1.84
Genome-wide scan for adult onset primary open angle glaucoma. Hum Mol Genet (2000) 1.82
Discovery of very-high-energy gamma-rays from the Galactic Centre ridge. Nature (2006) 1.81
Male homosexuality: absence of linkage to microsatellite markers at Xq28. Science (1999) 1.78
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Catamenial hemoptysis. Diagnosis with MRI. Chest (1997) 1.74
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler (2012) 1.74
CMA: a comprehensive Bioconductor package for supervised classification with high dimensional data. BMC Bioinformatics (2008) 1.68
B-cell alloantigen Ag 7a in multiple sclerosis. Lancet (1975) 1.67
Simian virus 40 enhancer increases RNA polymerase density within the linked gene. Nature (1985) 1.66
Radio imaging of the very-high-energy gamma-ray emission region in the central engine of a radio galaxy. Science (2009) 1.66
Reporting delay and corrected incidence of multiple sclerosis. Stat Med (1999) 1.65
Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler (2003) 1.64
Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler (2008) 1.64
Evaluating microarray-based classifiers: an overview. Cancer Inform (2008) 1.56
Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology (2000) 1.56
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 1.56
Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler (2009) 1.56
First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill (2013) 1.55
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler (2013) 1.55
High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation (2001) 1.54
Enhancer activity correlates with the oncogenic potential of avian retroviruses. EMBO J (1985) 1.52
Megadose corticosteroids in multiple sclerosis. Neurology (1994) 1.50
Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol (1995) 1.50
Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet (1991) 1.50
Structural and functional dissection of an MHC class I antigen-binding adenovirus glycoprotein. EMBO J (1986) 1.48
Radiologic diagnosis and management of complications related to central venous access. Acta Radiol (2003) 1.46
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
Infrainguinal aneurysm formation in arterialized autologous saphenous vein grafts. J Vasc Surg (1998) 1.44
A low level of extragalactic background light as revealed by gamma-rays from blazars. Nature (2006) 1.44
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
Fast variability of tera-electron volt gamma rays from the radio galaxy M87. Science (2006) 1.39
Increased risk for opportunistic infections during chemotherapy in HIV-infected patients with Kaposi's sarcoma. Dermatology (1997) 1.39
Response to the letter to the editor by William E. Seidelman: Hermann Stieve's clinical-anatomical research on executed women during the "Third Reich". Clin Anat (2009) 1.39
Care of central venous catheters for total parenteral nutrition. Nutr Clin Pract (1996) 1.38
[Magnetic resonance imaging of tibial periostitis]. J Radiol (1998) 1.38
Discovery of very high energy gamma rays associated with an x-ray binary. Science (2005) 1.38
New approach to patency and flow assessment after left internal thoracic artery hypoperfusion syndrome with additional saphenous vein graft to the left anterior descending artery with phase-contrast magnetic resonance angiography. J Thorac Cardiovasc Surg (1997) 1.38
Detection of gamma rays from a starburst galaxy. Science (2009) 1.38
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology (2005) 1.37
Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr (2010) 1.34
Transfer RNAs of potato (Solanum tuberosum) mitochondria have different genetic origins. Nucleic Acids Res (1990) 1.33
Mechanism of chaperonin action: GroES binding and release can drive GroEL-mediated protein folding in the absence of ATP hydrolysis. EMBO J (1996) 1.32
[A case of Goldenhar syndrome: acute vitamin A intoxication in the mother during pregnancy]. J Genet Hum (1975) 1.31
The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J Biol Chem (2001) 1.30
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest (1993) 1.27
Collateral circulation is an independent radiological predictor of outcome after thrombolysis in acute ischaemic stroke. Neuroradiology (2002) 1.26
Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease. Abdom Imaging (1995) 1.25
Identification of 21r and 22r chromosomes by quinacrine fluorescence. Clin Genet (1972) 1.25
Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler (2004) 1.24
Redundancy of information in enhancers as a principle of mammalian transcription control. J Mol Biol (1988) 1.23
Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler (2001) 1.22
Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology (1997) 1.21
Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology (1994) 1.19
Influence of morphine and naloxone on the release of noradrenaline from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol (1974) 1.19
Molecular cloning and characterization of WdPKS1, a gene involved in dihydroxynaphthalene melanin biosynthesis and virulence in Wangiella (Exophiala) dermatitidis. Infect Immun (2001) 1.18
Energy spectrum of cosmic-ray electrons at TeV energies. Phys Rev Lett (2008) 1.17
Association between transplantation antigens and a viral membrane protein synthesized from a mammalian expression vector. Cell (1983) 1.16
Age and disability accumulation in multiple sclerosis. Neurology (2011) 1.15
Interhospital transportation of patients with severe lung failure on pumpless extracorporeal lung assist. Br J Anaesth (2005) 1.14
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol (2000) 1.14
Multiple sclerosis after age 50. Neurology (1983) 1.13
Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis. J Invest Dermatol (2000) 1.13
Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler (2008) 1.12
[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients]. Rev Neurol (Paris) (2006) 1.12
Long-term survival of patients with multiple sclerosis in West France. Mult Scler (2007) 1.12
A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther (1999) 1.12
Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression. J Biol Chem (1995) 1.12
Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett (1996) 1.11